Syn120 (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 6 | パーキンソン病 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02258152 (ClinicalTrials.gov) | December 22, 2014 | 3/10/2014 | SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE) | SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE) | Parkinson's Disease Dementia (PDD) | Drug: SYN120;Drug: Placebo | Biotie Therapies Inc. | Michael J. Fox Foundation for Parkinson's Research;Massachusetts General Hospital;Acorda Therapeutics | Completed | 50 Years | N/A | All | 82 | Phase 2 | United States |